Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is a leading life science technology company with a comprehensive suite of solutions for analyzing biological systems at a high resolution and scale, positioning them well in the growing biotechnology industry. With a strong geographically diversified revenue stream and a promising pipeline of new products including the recently acquired Visium and Xenium platforms, the company is poised for continued growth. In addition, aggressive moves such as the acquisition of Prime Mining signal a commitment to expanding their portfolio and solidifying their position as a leader in the market.

Bears say

10x Genomics is facing potential headwinds as the company continues to repurchase shares and pay dividends, potentially limiting their ability to invest in new growth opportunities. Additionally, their current valuation multiples are lower than their peers, suggesting that the market has a negative outlook on the company's future growth potential. This may be due to concerns over the company's dependence on one product line and limited diversification in their revenue streams. Furthermore, their valuation and NAVPS ratios indicate that the stock is currently undervalued, possibly due to investors' lack of confidence in the company's long-term prospects.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.